ERC Advanced Grant – “Isolation and screening of human monoclonal antibodies against AMR for therapy and for discovery of novel vaccine antigens”
General aspects The reasearch project aims at producing vaccines able to contrast the antibiotics bacterial resistance. The project will last 5 years and represents one of the most important scientific challenges of our time, financed with 2,5 millions euros. The project, leaded by the scientist Rino Rappuoli, a pioneer in the vaccines field, obtained an European Research Council (ERC) Advanced Grant and will be realised in cooperation with Toscana Life Sciences Foundation as “host institution” which will make available laboratories, technology platforms and expertise inside an innovative and stimulating environment.
Research activities “Isolation and screening of human monoclonal antibodies against AMR for therapy and for discovery of novel vaccine antigens” aims, through the isolation of natural antibodies and the identification of recognised antigens, to develop vaccines able to destroy gonococcus, pneumococcus and Escherichia coli strains. In which way? Through the application of advanced technologies to reverse vaccinology developed by Rino Rappuoli at the end of ‘90s and now proposed again with a 2.0 approach. The idea, based on a completely sequenced genomes of pathogenic bacteria, allowed, in the last 20 years, to develop vaccines once very difficult to produce. Today, with the new “high speed” cloning possibilities, new opportunities were opened to contrast the antimicrobial resistance: a situation which already causes, according with the OMS, about 700.000 deceases per year with a forecast for 2025 of more than 10 millions deceased, even more than those caused nowadays by cancer.